Spiral Therapeutics Announces First Closing of a Series A Financing and Begins Phase 1 Trial of New Hearing Loss Drug

Spiral Therapeutics Announces First Closing of a Series A Financing and Begins Phase 1 Trial of New Hearing Loss Drug
Hugo Peris, founder and Chief Executive Officer of Spiral Therapeutics
  • December 31, 2018
  • News

Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies targeting inner ear disorders, today announced the initiation of its Phase 1 clinical trial of LPT99, the company’s lead investigational drug candidate targeting prevention and treatment of hearing loss.

Read more: https://www.prnewswire.com/news-releases/spiral-therapeutics-announces-first-closing-of-a-series-a-financing-and-begins-phase-1-trial-of-new-hearing-loss-drug-300767938.html

Close Menu